Investment Rating - The industry investment rating is "Outperform the Market" [1][32]. Core Insights - Johnson & Johnson's first-in-class drug, Icotrokinra, has been submitted for market approval in China, targeting moderate to severe plaque psoriasis in adults and children aged 12 and above. This drug is expected to achieve peak annual sales of over $5 billion [3][14]. - Icotrokinra is the first and only IL-23R targeted drug submitted for approval globally, with previous submissions in the US and Europe earlier this year [3][14]. - Johnson & Johnson has initiated a head-to-head study (ICONIC-ASCEND) to demonstrate the superiority of Icotrokinra over the injectable biologic, ustekinumab [3][14]. Summary by Sections Industry Overview - The report highlights the approval of Johnson & Johnson's Icotrokinra for treating moderate to severe plaque psoriasis, which has been prioritized for review by the CDE [3][14]. - The drug was developed with an investment of nearly $1 billion from Protagonist and is positioned as a significant innovation in the market [3][14]. Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as Hengrui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with high potential single products and leading technology platforms [5]. - The report emphasizes the increasing investment in pharmaceutical R&D and the potential for growth in emerging fields, recommending companies like WuXi AppTec and Kelun Pharmaceutical [5]. Market Performance - The pharmaceutical sector experienced a decline of 6.88% last week, ranking 23rd among 28 industries, while the Shanghai Composite Index fell by 3.77% [19][31]. - The report notes that the pharmaceutical sector's valuation stands at 29.49 times earnings, with a premium of 21.01% over the overall A-share market [25][31].